Study links new anticoagulants to higher GI bleeding risk

07/3/2013 | Healio

The new oral anticoagulants dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban may be linked to a higher risk of gastrointestinal bleeding compared with standard treatment, according to a study in the journal Gastroenterology. Researchers reviewed information from 43 randomized trials and concluded that more trials are needed to clarify the link.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD